Ki‐67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: Correlation with steroid receptors, epidermal‐growth‐factor receptor and cathepsin D

Ki‐67 immunoreactivity was studied in relation to immunohistochemically assessed expression of epidermal‐growth‐factor receptor (EGFR), estrogen receptor (ER) progesterone receptor (PgR) and cytosolic levels of cathepsin D in advanced human ovarian adenocarcinomas, borderline and benign cystadenomas and normal ovaries. A significantly higher number of Ki‐67‐positive cells were found in metastatic tumors vs. primary adenocarcinomas and in the total group of adenocarcinomas vs. benign/borderline cystadenomas. Cathepsin‐D levels were also significantly higher in metastatic tumors than in primary adenocarcinomas, which in turn presented higher levels than were found in normal ovaries. However, no significant difference was observed between cathepsin‐D levels in malignant adenocarcinomas and borderline/benign cystadenomas. Immunohistochemically assessed expression of ER and PgR was detected in variable percentages of epithelial tumor cells, and stromal cells were occasionally positive as well. In the group of primary adenocarcinomas, 46% were ER‐positive and 34% were PgR‐positive, although there was no significant difference between primary and metastatic lesions with respect to ER or PgR expression. Concordance between immunohistochemically assessed ER or PgR data and cytosolic ER and PgR levels measured with enzyme immunoassay was relatively low. EGFR, immunohistochemically assessed with MAb‐EGFRI, was positive in 76% of the primary and in 78% of the metastatic adenocarcinomas. A strong positive association was detected between ER and PgR, and EGFR was observed to present a weak positive correlation with Ki‐67 and ER. Cathepsin‐D levels were not found to be significantly correlated with the expression of ER, PgR, EGFR or Ki‐67. © 1994 Wiley‐Liss, Inc.

[1]  J. Foekens,et al.  Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Foekens,et al.  The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. , 1993, European journal of cancer.

[3]  J. Foekens,et al.  Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay. , 1992, British Journal of Cancer.

[4]  J. Foekens,et al.  Receptors for hormones and growth factors and (ONCO)‐gene amplification in human ovarian cancer , 1992, International journal of cancer.

[5]  J G Klijn,et al.  The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. , 1992, Endocrine reviews.

[6]  R. Leake,et al.  Epidermal growth factor receptors (EGFR) in human ovarian cancer. , 1991, British Journal of Cancer.

[7]  G. Scambia,et al.  Cathepsin D assay in ovarian cancer: correlation with pathological features and receptors for oestrogen, progesterone and epidermal growth factor. , 1991, British Journal of Cancer.

[8]  T. H. van der Kwast,et al.  Ki-67 staining in histological subtypes of breast carcinoma and fine needle aspiration smears. , 1991, Journal of clinical pathology.

[9]  B. Slotman,et al.  Endocrine factors in common epithelial ovarian cancer. , 1991, Endocrine reviews.

[10]  R. Bast,et al.  Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[11]  T. Bauknecht,et al.  Clinical significance of oncogenes and growth factors in ovarian carcinomas , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[12]  O. Kallioniemi,et al.  Steroid receptors and Ki‐67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survival , 1990, The Journal of pathology.

[13]  H. Rochefort,et al.  Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. , 1990, Molecular endocrinology.

[14]  R. Bast,et al.  The Role of Peptide Growth Factors in Epithelial Ovarian Cancer , 1990, Obstetrics and gynecology.

[15]  M. Tattersall,et al.  Immunohistochemical determination of tumour growth fraction in human ovarian carcinoma , 1989, British journal of obstetrics and gynaecology.

[16]  H. Rochefort,et al.  In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. , 1988, Cancer research.

[17]  T. Bauknecht,et al.  Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. , 1988, Gynecologic oncology.

[18]  Marcel Garcia,et al.  Estrogen‐induced lysosomal proteases secreted by breast cancer cells: A role in carcinogenesis? , 1987, Journal of cellular biochemistry.

[19]  W. Franklin,et al.  Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast , 1987, Cancer.

[20]  A. V. van Lindert,et al.  DNA flow cytometry, histological grade, stage, and age as prognostic factors in human epithelial ovarian carcinomas. , 1987, Pathology, research and practice.

[21]  G. Sutton,et al.  Estrogen and progesterone receptors in epithelial ovarian malignancies. , 1986, Gynecologic oncology.

[22]  H. Rochefort,et al.  A secreted glycoprotein induced by estrogen in human breast cancer cell lines , 1980, Cell.